BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241202
DTEND;VALUE=DATE:20241205
DTSTAMP:20260515T130921
CREATED:20240808T110905Z
LAST-MODIFIED:20240808T110905Z
UID:39544-1733097600-1733356799@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year’s explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. \nThis year’s agenda brings you the opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication. Leading experts including Cartesian Therapeutics\, Bristol Myers Squibb\, the University of Pennsylvania\, ImmPACT Bio and more\, will cover their latest clinical updates\, next-generation candidates\, novel antigen targets\, and translational biomarkers to turbocharge the development of cell therapies for autoimmune disease. \nThis is your chance to connect with top cell therapy pioneers\, clinicians\, investors\, and wavemakers who share a focus on accelerating this approach for autoimmune patients to realize a curative treatment. \nFind out more here.
URL:http://www.pharmajournalist.com/event/2nd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T130921
CREATED:20240808T111110Z
LAST-MODIFIED:20240808T111110Z
UID:39549-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:6th Cell Therapy Analytical Development Summit
DESCRIPTION:As the field of cell therapy evolves\, integrating the latest technologies and robust analytical methods has never been more crucial. Join us at the 6th Cell Therapy Analytical Development Summit to discover how to enhance your analytical strategies and accelerate product development through IND and clinical trials\, leading to more efficient regulatory approval. \nWhy Attend? \n\nExplore the latest advancements in immunophenotype\, cell-based\, and molecular assays.\nConnect with over 40 industry leaders and experts from companies like Bristol Myers Squibb\, Takeda\, and Kite Pharma to delve into assay matrices\, phase-appropriate development\, and specifications.\nParticipate in discussions on overcoming challenges in product characterization\, assay development\, and scale-up\, sharing innovative technologies and best practices to advance cell therapies.\n\nJoin us to elevate the development of safe and effective autologous and allogeneic cell therapies to new heights! \nDownload the NEW 2024 program
URL:http://www.pharmajournalist.com/event/6th-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T130921
CREATED:20240809T123626Z
LAST-MODIFIED:20240813T083728Z
UID:39561-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:Personalized Vaccine Summit
DESCRIPTION:The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA\, DNA\, peptides\, viral\, dendritic cell and more to share how they are conquering common challenges\, developing novel bioinformatic strategies\, and achieving clinical efficacy. \nThis is the only conference uniting biopharma companies working on different vaccine modalities to develop an immune-responsive personalized cancer vaccine for one goal – cure cancer! Join the likes of BioNTech\, CureVac\, Imvax\, NousCom\, with our expert speaker faculty of leaders and industry pioneers\, for 3 days of content and 15+ deep dive case studies. \nInterested? Find out more here. https://ter.li/lg5a1h
URL:http://www.pharmajournalist.com/event/personalized-vaccine-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T130921
CREATED:20240919T065329Z
LAST-MODIFIED:20240920T112649Z
UID:39788-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:5th Genome Editing Therapeutics Summit
DESCRIPTION:Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery\, Casgevy marks the first approved gene-editing therapy\, a major milestone for the field. This breakthrough signals the beginning of a revolution in treating genetic diseases\, with a rapidly growing pipeline of precision genome-editing techniques emerging. \n \nThe 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Sumit) is the leading industry event dedicated to advancing gene-editing technologies in therapy. Attendees can expect data-rich presentations\, expert panels\, and interactive sessions covering both established and emerging technologies. The summit will explore key topics such as novel nucleases\, base and prime editing\, multiplex editing\, and precision tools enabling small and large genome modifications. Additionally\, it will highlight epigenome editing\, recombinase and transposon-based technologies\, and innovative delivery vehicles. \nOver three days\, industry and academic leaders will present the latest research on cutting-edge therapies\, discussing the safety\, precision\, and regulatory compliance necessary for successful development. This summit is the only event prioritizing drug development first\, with a strong focus on creating robust safety profiles\, detecting off-target effects\, and facilitating investigational new drug (IND) filings. \nParticipants will gain actionable insights to improve the precision and safety of their technologies\, enhancing their ability to perform targeted edits and streamline the path to the clinic for lead programs. \nJoin us and be part of the gene-editing revolution shaping the future of therapeutic development!
URL:http://www.pharmajournalist.com/event/5th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T130921
CREATED:20240719T112018Z
LAST-MODIFIED:20240722T133910Z
UID:39410-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:2nd Covalent Drug Discovery & Development Summit
DESCRIPTION:Discover & Develop Selective\, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology\, Immunology & Beyond \nThe covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology\, immunology and CNS. Yet\, key challenges remain in balancing reactivity and sensitivity\, de-risking the ligandability of alternative residues\, and tackling PKPD disconnects and efficiency bottlenecks\, \nBringing together 100+ covalency experts\, the 2nd Covalent Drug Discovery & Development Summit returns as the only dedicated forum to comprehensively cover discovery to translation and clinical development of covalent therapeutics. \n\nDates: December 10-12\, 2024\nLocation: Hilton Boston Logan Airport\, Boston\, Massachusetts\nEvent Program: https://ter.li/bz5jjg\n\nDive into extensive technical content spanning target selectivity\, hit screening\, lead optimization and covalent warhead design\, network with over 100 heads\, directors and VPs of Proteomics\, Medicinal Chemistry\, Chemical Biology\, Discovery Biology and Pharmacology\, and hear from the brightest minds of academia as they share their latest findings. \nDownload the program here: https://ter.li/bz5jjg \nRegister your place here (and take advantage of group discounts of up to 20% when registering your team of two or more!): https://ter.li/8257lj
URL:http://www.pharmajournalist.com/event/2nd-covalent-drug-discovery-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T130921
CREATED:20240828T105923Z
LAST-MODIFIED:20240828T105923Z
UID:39639-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:With recent accelerated approval wins\, positive clinical trial readouts\, progression through clinical pipelines and exciting mergers and acquisitions\, it has certainly been an industry-defining year for the rare and genetic renal space. \nIn the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients\, the 4th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry\, academic KOL\, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations. \nJoin Mironid\, AstraZeneca\, Novartis\, Maza Therapeutics\, Harvard Medical School\, and more as you dive into critical topics investigating IgAN\, FSGS\, PKD\, Alport Syndrome and more therapeutic areas to foster partnerships and accelerate game-changing therapies into the clinic and to rare renal diseases patients in need. \nView the full event program here: https://ter.li/ncjxqh
URL:http://www.pharmajournalist.com/event/4th-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T130921
CREATED:20240828T110543Z
LAST-MODIFIED:20240828T110543Z
UID:39644-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:7th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus\, there have been many valuable collaborations entering the RNA-targeting field\, accelerating efficacious and selective small molecules targeting RNA directly\, RNA-binding proteins\, and RNA/protein complexes. \nHence\, as the go-to meeting for the RNA-targeting small molecule community\, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures\, delve into innovative preclinical modeling strategies\, and identify optimal chemical features for advancing specific\, efficacious\, and safe small molecules. \nCurated in collaboration with large pharma\, innovative biotech\, and leading academics\, the 7th RNA-Targeted Drug Discovery & Development Summit returns with 3 jam-packed days and unrivaled networking opportunities with the key stakeholders to accelerate the discovery of disease-relevant RNA\, optimize small molecule design\, and uncover novel targets on proteins\, enzymes\, and RNA/protein complexes to increase the landscape of treatable diseases. \nUnite with 100+ RNA Science\, Medicinal Chemistry\, Structural Biology & Biophysics experts from the likes of AstraZeneca\, Sanofi\, Novartis\, PTC Therapeutics\, ReviR Therapeutics\, Rgenta Therapeutics\, Accent Therapeutics\, and more at the most comprehensive and definitive event for the community\, the 7th RNA-Targeted Drug Discovery & Development Summit\, to accomplish faster and smoother translation of RNA-targeted therapies towards the clinic. \nTo know more visit: www.rna-drugdiscovery.com
URL:http://www.pharmajournalist.com/event/7th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T130921
CREATED:20240904T120903Z
LAST-MODIFIED:20240904T120903Z
UID:39686-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:8th Complement-Based Drug Development Summit
DESCRIPTION:With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH\, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies? \nWith assets in nephrology\, ophthalmology\, neurodegeneration\, and inflammation all progressing through to the clinic\, the immunology landscape is preparing to be shaken up with companies making huge strides to achieve and improve the efficacy of complement-targeted therapies. \nJoin 100+ industry leaders\, scientists\, and clinicians at the premier\, end-to-end\, 8th Complement-Based Drug Development Summit to shape the future of complementtargeted therapies. Across 3 days of content\, you can expect discussions spanning: \n\nStrategic targeting and preclinical breakthroughs for the next-generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets\nNavigating complement clinical trials and exploring indication expansion strategy for complement inhibitors beyond their initial disease indication\nExploring the potential for combination therapies to overcome compensatory mechanisms and ensure patient comfort\nMoving from targeting rare disease with complement inhibitors to larger patient populations\nNavigating efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster\n\nKey benefits of attending: \n\nDelve into the pathophysiology of different complement pathways for the specific targeting of acute and chronic inflammatory diseases with Apterion Therapeutics\, Annexon Bio\,and Sanofi to determine the most effective pathway when developing complement inhibitors\nExplore the potential for combination therapies with existing complement therapies and other modalities with CSL Behring for a more precise approach to hit inflammation and autoimmune diseases harder beyond complete immunosuppressive approaches.\nDiscuss the move from targeting rare diseases with complement inhibitors to more common diseases with IgM Biosciences\, Grid Therapeutics\,and Astellas\, to target larger patient populations\nEvaluate the value proposition of targeting complement proteins with advanced therapeutics such as RNAi and gene therapies to determine the optimal mode of action and make complement inhibitors more targeted with Beacon Therapeutics and Arrowhead Pharmaceuticals\n8 Brand New Data readouts focusing on the translational and clinical stages of complement inhibitor development to help you stay up to date as this field makes strides towards regulatory approval
URL:http://www.pharmajournalist.com/event/8th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T130921
CREATED:20240930T131805Z
LAST-MODIFIED:20240930T131943Z
UID:39832-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th ADC Target Selection Summit
DESCRIPTION:The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target to support with the development of future first-in-class ADCs. \nWith sessions led by Almac Discovery\, AstraZeneca\, Bolt Biotherapeutics\, and many other industry leaders\, leave this meeting equipped to perform a strategic evaluation of when and how to approach developing an ADC against a novel target. Enhance this knowledge with exclusive insight from brand-new biotechs\, Epifold and GO Therapeutics striving to leave their mark on the ADC field by sharing their innovative strategy which has reaped success in novel ADC targeting. \nDon’t miss this opportunity to join an audience of 80+ highly focused biologists\, discovery researchers\, computational biologists and bioinformaticians\, as well as senior C-level and Alliance Management experts. End your 2024 ADC conference calendar with the perfect balance of scientific and strategic level conversations and gain the know-how to invigorate your target selection strategy and propel more ADCs to first-in-class therapeutics. \nView all the industry strategies\, innovation sessions and networking opportunities in the FREE event guide here: https://ter.li/un31n9
URL:http://www.pharmajournalist.com/event/4th-adc-target-selection-summit/
LOCATION:DoubleTree by Hilton Hotel\, San Diego Downtown\, 1646 Front Street\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T130921
CREATED:20241114T161818Z
LAST-MODIFIED:20241114T161908Z
UID:40104-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:The 4th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Join industry leaders like Eli Lilly\, Merck\, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12\, 2024 – Philadelphia\, PA). This is your perfect moment to network with enzyme discovery\, engineering\, biocatalysis\, and process chemistry professionals from both industry and academia. \nCapitalize on Enzyme Evolution through HTP Screening\, Advanced Engineering & Deploy Maturing Biocatalysis Techniques in Small Molecules & Complex Modalities. \nNow with a sharper focus on enzyme engineering and expanded coverage of biocatalysis-derived oligonucleotides\, peptides and other large biologics. Plus\, dive into brand-new biopharma case studies designed to boost enzyme efficiency and therapeutic yields. \nWhy Attend? \n– Revolutionize Biologics Development: Discover cutting-edge oligonucleotide production case studies that are setting new standards in biologics \n– Streamline Enzyme Discovery: Learn how to prioritize and engineer enzymes from early-stage proof of concept to accelerate your pipeline \n– Fast-Track Decision Making: Master modern prediction methods and sophisticated high-throughput techniques to refine enzyme selection \n– Optimize Small Molecule Biocatalysis: Gain insights from pharma-led projects focused on enhancing activity\, yields and green chemistry \nWhat to Expect? \n– Exclusive interactive discussions exploring ML-informed enzyme design techniques \n– Poster session opportunity to showcase your current work and gain feedback from 60+ senior peers \n– 20+ industry speakers to inspire you and help you take advantage of biocatalysis in its prime \n– Pharma and academia-led workshops to perfect enzyme decision-making and late process optimization \nLet’s innovate and elevate drug development pipelines together through the power of green biocatalysis. \nTo know more visit: https://ter.li/t9gd14
URL:http://www.pharmajournalist.com/event/the-4th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241211
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T130921
CREATED:20241108T100238Z
LAST-MODIFIED:20241108T100238Z
UID:40052-1733875200-1734047999@www.pharmajournalist.com
SUMMARY:3rd PAT & Real Time Quality Summit
DESCRIPTION:Join 100+ leading PAT scientists\, engineers\, process development\, CMC\, MSAT and quality experts at the 3rd Annual PAT & Real Time Quality Summit. Explore cutting-edge data-driven case studies\, engage in dynamic roundtables and deep dive into KOL-led panel debates. This summit is your gateway to staying ahead of the innovation curve\, exceeding stakeholder expectations for faster time to market\, and unlocking significant ROI through transformative PAT and real-time quality control. \nWith drug developers and manufacturers facing closer scrutiny on product quality than ever before\, it’s time to make the most of evolving process analytical technology (PAT) to design robust and cost-effective control strategies to understand more about your biopharmaceutical products. \nRecent blockbusters like GLP-1 peptides have sparked unprecedented investment into advanced manufacturing strategies\, such as Novo Nordisk’s recent $11B acquisition to expand manufacturing capacity. The maturity of PAT tools and the development of sophisticated software and chemometrics now provide the perfect opportunity to revolutionize traditional quality and analytical approaches\, achieving the digital manufacturing maturity necessary for the future. \nDon’t miss your chance to connect ground-breaking technologies with real-world manufacturing investment decisions. This is the only PAT conference designed exclusively for the pharmaceutical and biopharmaceutical community\, where insights turn into action. \nTo know more visit: https://ter.li/e3xja8
URL:http://www.pharmajournalist.com/event/3rd-pat-real-time-quality-summit/
LOCATION:Philadelphia Airport Marriott\, Terminal B\, One Arrivals Road Terminal B\, Arrivals Rd\, Philadelphia\, PA\, 19153\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR